[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Doddi S, Singhal T, De Silva C, Smedley F, Sinha P, Leslie M: Small cell carcinoma of the anus: a case report. Cases J; 2009;2:9396

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the anus: a case report.
  • Small cell carcinoma of the anus is a very rare but aggressive tumour.
  • We present a case of a 60-year old lady with small cell carcinoma of the anus.
  • She had chemotherapy and radiotherapy but developed distant metastasis after completion of treatment.
  • Immunohistochemistry is required to make a diagnosis.
  • Chemotherapy remains the mainstay of treatment for small cell carcinoma of the anus with or without metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1068-76 [17614337.001]
  • [Cites] Histopathology. 2007 Jan;50(1):163-74 [17204029.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3156-8 [15918209.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12):692-3 [18852720.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Surg Today. 2002;32(1):72-4 [11871823.001]
  • [Cites] Surg Today. 1993;23(1):85-8 [8384908.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):635-42 [8026228.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • (PMID = 20076782.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806881
  •  go-up   go-down


2. Meyer A, Bruns F, Richter K, Grünwald V, Karstens JH: Small cell cancer of the anal canal--case report of a rare tumor. Anticancer Res; 2007 Mar-Apr;27(2):1047-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the anal canal--case report of a rare tumor.
  • BACKGROUND: We report on a rare case of small cell cancer located at the anal canal.
  • CASE REPORT: A 41-year old woman presented with locally advanced small cell anal cancer and simultaneous hepatic and pulmonal deposits.
  • Due to metastatic disease, chemotherapy with etoposide and cisplatin was performed with mixed response after four cycles of chemotherapy.
  • After application of two additional chemotherapy cycles, locally progressive disease occurred causing symptomatic bowel obstruction.
  • Despite adequate local treatment the patient's condition further deteriorated and irradiation was stopped.
  • The patient died 10 months after initial diagnosis due to rapid tumor progression.
  • CONCLUSION: In patients with metastatic small cell anal cancer chemotherapy remains the mainstay of therapy.
  • Careful histopathological examination, together with immunohistochemistry, is needed to determine the therapeutic strategy to be followed.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465242.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Guimarães AP, Matos D, Segreto R, Forones NM: [Squamous cell carcinoma of the canal anal]. Arq Gastroenterol; 2001 Jan-Mar;38(1):9-13
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the canal anal].
  • [Transliterated title] Carcinoma espinocelular de canal anal: análise de 11 casos.
  • BACKGROUND: Anal cancer is an uncommon malignancy accounting for only a small (4%) percentage of intestinal cancer.
  • The authors described the clinical aspects and the treatment of the patients with squamous cell carcinoma of the canal anal.
  • PATIENTS: Eleven patients with squamous cell carcinoma treated among 1995 and 1999, were analyzed retrospectively.
  • Six of them had previous anal benign disease and two had metastases at the diagnosis.
  • All were submitted to systemic chemotherapy with 5-fluorouracil and mitomycin and radiotherapy with 4500 cGy.
  • The chemo radiation can be a curable treatment in patients with local disease; conversely in patients with residual disease, abdominoperineal resection must be done.
  • Although anal cancer is an often curable disease, four patients died because the diagnosis was done in advanced stage.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11582966.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Chapet O, Corcelle-Requin A, Padovani L, Bizollon MH, Mérieux C, Trillet-Lenoir V, Gérard JP: [Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases]. Rev Med Interne; 2001 Nov;22(11):1109-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases].
  • INTRODUCTION: Anorectal neuroendocrine small cell carcinomas are rare and frequently difficult to treat.
  • Histology displayed neuron-specific enolase and chromogranin A immunoreactive small cell tumors.
  • Tumors were poorly reactive to chemotherapy and irradiation, less than in usual epidermoid anal canal cancer.
  • CONCLUSION: Anorectal neuroendocrine small cell carcinomas are rare but need to be individualized from epidermoid anal canal tumors owing to their poor prognosis with a frequent occurrence of hepatic and pulmonary metastasis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11817122.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • All patients were scheduled for simultaneous chemotherapy with two cycles of 5-fluorouracil at a dose of 1000 mg/m (2)/day as 120 hours of continuous intravenous infusion on Days 1 to 5 and 29 to 33 and mitomycin C at 10 mg/m (2)/day on Days 1 and 29.
  • Median follow-up time was was 7.5 (range, 1-16) years.
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Treatment evolved from radiotherapy with or without surgery, to preoperative chemoradiotherapy, to definitive chemoradiotherapy (CRT).
  • No association was found with gender, age, preoperative vs. definitive CRT, or human immunodeficiency virus status.
  • The radiotherapy factors associated with Grade 3 or greater late morbidity included anorectal morbidity with tumor dose (29% with a dose > or =55 Gy vs. 9% otherwise), small bowel injury with technique (9% with anteroposterior-posteroanterior supine vs. 0.7% with multiple fields prone), and bone injury with femoral head dose (9% with a dose of > or =44 Gy vs. 0.7% otherwise).
  • We also discuss the treatment planning implications of the late morbidity findings.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Combined Modality Therapy / trends. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. HIV Seropositivity / complications. Hospitals, University. Humans. Male. Middle Aged. Missouri. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Radiation-Induced / pathology. Radiation Injuries / pathology. Radiotherapy Dosage. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251377.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Glynne-Jones R, Hoskin P: Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol; 2007 Nov 20;25(33):5281-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?
  • Effective chemotherapy (CT) treatment of solid tumors emerged with the introduction of anthracyclines and platinum CT in the late 1970s, at first with palliative intent, and later extended into the adjuvant setting.
  • A new strategy advocated cisplatin-based neoadjuvant CT (NACT) before definitive local treatment-either surgery or radiotherapy (RT).
  • The aim of this discussion is to raise the debate regarding NACT in reducing metastases, improving local control and selecting out good responders for nonsurgical treatment in the following sites: head and neck, esophagus, cervix, anus, nasopharynx, and bladder; as well as non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Chemotherapy, Adjuvant. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoadjuvant Therapy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Mar 20;26(9):1562-3; author reply 1563 [18349411.001]
  • [CommentIn] J Clin Oncol. 2008 Aug 1;26(22):3669-71 [18519948.001]
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):e1-2 [18375883.001]
  • (PMID = 18024876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 67
  •  go-up   go-down


8. Vuong T, Devic S, Belliveau P, Muanza T, Hegyi G: Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys; 2003 Jul 1;56(3):823-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.
  • PURPOSE: To evaluate the feasibility of delivering conformal radiotherapy (RT) and concurrent chemotherapy without a mandatory break in patients with anal canal carcinoma.
  • METHODS AND MATERIALS: Thirty patients with T2-T4 tumors were treated with a combination of 54 Gy in 30 fractions and two cycles of 5-fluorouracil and mitomycin C.
  • Dose-volume histograms were obtained for bone marrow, small bowel, and skin to compare the conventional technique using the Radiation Therapy Oncology Group standard with our conformal technique.
  • RESULTS: The mean dose ratio of the conventional compared with the conformal technique for bone marrow, small bowel, and skin was, respectively, 2.1-2.7, 3.0, and 2.0, in favor of the conformal technique.
  • All patients completed their treatment without a treatment break.
  • CONCLUSION: The results of this study have shown that conformal RT leads to a well-tolerated treatment.
  • The treatment time is shortened to 6 weeks.
  • A significant decrease in the acute toxicity rate suggests that by decreasing the "volume factor," conformal RT improves the therapeutic index in patients treated with combined chemotherapy and RT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / prevention & control. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12788191.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Ryan DP, Mayer RJ: Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol; 2000 Jul;12(4):345-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma: histology, staging, epidemiology, treatment.
  • Our understanding of the pathogenesis and management of squamous cell carcinoma of the anal canal has undergone profound change over the last 30 years.
  • Primary treatment with concomitant chemotherapy and radiation cures the majority of patients without the need for an abdominoperineal resection.
  • The incorporation of cisplatin into the primary chemoradiation treatment of patients with carcinoma of the anal canal is the focus of current studies.
  • [MeSH-major] Adenocarcinoma. Anus Neoplasms. Carcinoma, Small Cell. Carcinoma, Squamous Cell
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10888420.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 93
  •  go-up   go-down


10. Myerson RJ, Kong F, Birnbaum EH, Fleshman JW, Kodner IJ, Picus J, Ratkin GA, Read TE, Walz BJ: Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol; 2001 Oct;61(1):15-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome.
  • BACKGROUND AND PURPOSE: In recent years, treatment with combined chemotherapy and radiation has become the standard of care for epidermoid carcinoma of the anus.
  • MATERIALS AND METHODS: During the period 1975-1997, 106 patients with epidermoid carcinoma of the anal canal underwent radiation therapy.
  • Treatment policies evolved from radiation therapy alone or with surgery, to combined chemotherapy and radiation followed by surgery, to combined chemotherapy and radiation.
  • CONCLUSIONS: For T1/T2N0 disease, moderate doses of radiation combined with chemotherapy provided adequate treatment.
  • The volume of irradiated small bowel should be minimized for patients who have a past history of major pelvic surgery or who (because of locally advanced tumors) may need salvage surgery in the future.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Precipitating Factors. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11578724.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


11. Rabbitt P, Pathma-Nathan N, Collinson T, Hewett P, Rieger N: Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal. ANZ J Surg; 2002 Sep;72(9):651-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal.
  • BACKGROUND: The current Trans-Tasman Radiation Oncology Group (TROG) protocol for T1 and T2 anal cancers is combination chemotherapy and radiotherapy excluding the inguinal region from the field.
  • Several centres worldwide irradiate both inguinal regions as there is a small incidence of involvement with early stage tumours.
  • We have developed a method of sampling the sentinel node in the groin using established node mapping techniques.
  • CONCLUSIONS: The application of this effective technique will allow accurate staging of anal cancers to better plan future treatment regimes.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269917.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Fesneau M, Champeaux-Orange E, Hennequin C: [Anal cancer]. Cancer Radiother; 2010 Nov;14 Suppl 1:S120-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For localized diseases, the treatment is based on radiotherapy with or without chemotherapy (5-FU and cisplatin or mitomycin), according to tumour and nodal extension.
  • The recommended treatment dose is 45 Gy in the anal canal, the mesorectum, pararectal lymph nodes, and inguinal lymph nodes.
  • An additional dose of 15 to 20 Gy is delivered in the initial tumour for good responders.
  • The organs at risk to be considered are bladder, femur heads, small intestine and vulva.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Dosage
  • [MeSH-minor] Combined Modality Therapy. France. Humans. Incidence. Prognosis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129654.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • For although it is one of the few malignancies that may be cured with chemoradiation alone, the use of combined modality therapy may result in significant treatment-related morbidity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


15. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only small numbers of bona fide examples exist in the world literature; cases arising primarily at extranodal sites are not well described and often seem to go unrecognized.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Durdux C: [Cisplatin and derivatives with radiation therapy: for what clinical use?]. Cancer Radiother; 2004 Nov;8 Suppl 1:S88-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cisplatin and derivatives with radiation therapy: for what clinical use?].
  • The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives.
  • [MeSH-major] Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Anus Neoplasms / drug therapy. Anus Neoplasms / mortality. Anus Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Leukemia P388 / drug therapy. Leukemia P388 / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / radiotherapy. Meta-Analysis as Topic. Mice. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Rats. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Time Factors. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679253.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Radiation-Sensitizing Agents; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 71
  •  go-up   go-down


17. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • Malignant neoplasms of the anus were excluded for the purposes of this study.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.






Advertisement